CD169	B:C1608815
identifies	O
an	O
activated	O
CD8	O
(+)	I:C0242629

CD169	O
identifies	B:C0243095
an	O
activated	O
CD8	O
(+)	I:C0242629

CD169	O
identifies	O
an	O
activated	B:C1515879
CD8	O
(+)	I:C0242629

CD169	O
identifies	O
an	O
activated	O
CD8	B:C0242629
(+)	I:C0242629

T	I:C0242629
cell	I:C0242629
subset	B:C0079720
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
that	O
predicts	O
favorable	O
prognosis	O
in	O
colorectal	O
cancer	I:C1527249
patients	O
.	O

T	I:C0242629
cell	I:C0242629
subset	O
in	O
regional	B:C1179441
lymph	I:C1179441
nodes	I:C1179441
that	O
predicts	O
favorable	O
prognosis	O
in	O
colorectal	O
cancer	I:C1527249
patients	O
.	O

T	I:C0242629
cell	I:C0242629
subset	O
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
that	O
predicts	O
favorable	O
prognosis	B:C0033325
in	O
colorectal	O
cancer	I:C1527249
patients	O
.	O

T	I:C0242629
cell	I:C0242629
subset	O
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
that	O
predicts	O
favorable	O
prognosis	O
in	O
colorectal	B:C1527249
cancer	I:C1527249
patients	O
.	O

CD169	B:C1608815
was	O
first	O
identified	O
on	O
macrophages	O
(	O
macrophages	O
)	O
and	O
linked	O
to	O
antigen	O
presentation	I:C0206431
.	O

CD169	O
was	O
first	O
identified	O
on	O
macrophages	B:C0024432
(	O
macrophages	O
)	O
and	O
linked	O
to	O
antigen	O
presentation	I:C0206431
.	O

CD169	O
was	O
first	O
identified	O
on	O
macrophages	O
(	O
macrophages	B:C0024432
)	O
and	O
linked	O
to	O
antigen	O
presentation	I:C0206431
.	O

CD169	O
was	O
first	O
identified	O
on	O
macrophages	O
(	O
macrophages	O
)	O
and	O
linked	O
to	O
antigen	B:C0206431
presentation	I:C0206431
.	O

Here	O
,	O
we	O
showed	O
CD169	B:C0017262
expression	I:C0017262
on	O
some	O
CD8	O
(+	I:C0242629
)	I:C0242629

Here	O
,	O
we	O
showed	O
CD169	O
expression	I:C0017262
on	O
some	O
CD8	B:C0242629
(+	I:C0242629
)	I:C0242629

T	I:C0242629
lymphocytes	I:C0242629
in	O
regional	B:C1179441
lymph	I:C1179441
nodes	I:C1179441
(	O
lymph	O
nodes	I:C1179441
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	O
relevance	I:C0243095
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0242629
lymphocytes	I:C0242629
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
(	O
lymph	B:C1179441
nodes	I:C1179441
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	O
relevance	I:C0243095
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0242629
lymphocytes	I:C0242629
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
(	O
lymph	O
nodes	I:C1179441
)	O
and	O
investigated	O
the	O
function	B:C0031843
and	O
clinical	O
relevance	I:C0243095
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0242629
lymphocytes	I:C0242629
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
(	O
lymph	O
nodes	I:C1179441
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	B:C0243095
relevance	I:C0243095
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0242629
lymphocytes	I:C0242629
in	O
regional	O
lymph	I:C1179441
nodes	I:C1179441
(	O
lymph	O
nodes	I:C1179441
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	O
relevance	I:C0243095
of	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
in	O
tumor	B:C0024204
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
patients	O
.	O

T	I:C0039194
cells	I:C0039194
in	O
tumor	O
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
of	O
colorectal	B:C1527249
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
patients	O
.	O

T	I:C0039194
cells	I:C0039194
in	O
tumor	O
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	B:C1527249
cancer	I:C1527249
)	O
patients	O
.	O

Fresh	B:C0440747
tumor	I:C0440747
-	I:C0440747
draining	I:C0440747
LN	I:C0440747
tissues	I:C0440747
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	O
cytometry	I:C0016263
for	O
activation	O
and	O
differentiation	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

Fresh	O
tumor	I:C0440747
-	I:C0440747
draining	I:C0440747
LN	I:C0440747
tissues	I:C0440747
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	B:C0016263
cytometry	I:C0016263
for	O
activation	O
and	O
differentiation	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

Fresh	O
tumor	I:C0440747
-	I:C0440747
draining	I:C0440747
LN	I:C0440747
tissues	I:C0440747
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	O
cytometry	I:C0016263
for	O
activation	O
and	O
differentiation	B:C0007589
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

Fresh	O
tumor	I:C0440747
-	I:C0440747
draining	I:C0440747
LN	I:C0440747
tissues	I:C0440747
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	O
cytometry	I:C0016263
for	O
activation	O
and	O
differentiation	O
of	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
and	O
T	B:C1523368
cell	I:C1523368
-	I:C1523368
mediated	I:C1523368
killing	I:C1523368
of	I:C1523368
tumor	I:C1523368
cells	I:C1523368
.	O

In	O
total	O
,	O
114	O
tumor	B:C0024204
-	I:C0024204
draining	I:C0024204
LN	I:C0024204
paraffin	O
sections	O
from	O
colorectal	O
cancer	I:C1527249
patients	O
were	O
analyzed	O
by	O
multiple	O
-	I:C0016318
color	I:C0016318
immunofluorescence	I:C0016318
for	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
total	O
,	O
114	O
tumor	O
-	I:C0024204
draining	I:C0024204
LN	I:C0024204
paraffin	O
sections	O
from	O
colorectal	B:C1527249
cancer	I:C1527249
patients	O
were	O
analyzed	O
by	O
multiple	O
-	I:C0016318
color	I:C0016318
immunofluorescence	I:C0016318
for	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
total	O
,	O
114	O
tumor	O
-	I:C0024204
draining	I:C0024204
LN	I:C0024204
paraffin	O
sections	O
from	O
colorectal	O
cancer	I:C1527249
patients	O
were	O
analyzed	O
by	O
multiple	B:C0016318
-	I:C0016318
color	I:C0016318
immunofluorescence	I:C0016318
for	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
total	O
,	O
114	O
tumor	O
-	I:C0024204
draining	I:C0024204
LN	I:C0024204
paraffin	O
sections	O
from	O
colorectal	O
cancer	I:C1527249
patients	O
were	O
analyzed	O
by	O
multiple	O
-	I:C0016318
color	I:C0016318
immunofluorescence	I:C0016318
for	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

The	O
prognostic	B:C0220901
significance	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

The	O
prognostic	O
significance	O
of	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
was	O
evaluated	B:C0220825
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O

A	O
fraction	O
of	O
CD8	B:C0242629
(+	I:C0242629
)	I:C0242629

T	I:C0242629
cells	I:C0242629
in	O
regional	B:C1179441
LNs	I:C1179441
,	O
but	O
not	O
peripheral	O
blood	I:C0229664
,	O
tonsils	O
,	O
or	O
tumors	O
,	O
expressed	O
surface	I:C1608815
CD169	I:C1608815
.	O

T	I:C0242629
cells	I:C0242629
in	O
regional	O
LNs	I:C1179441
,	O
but	O
not	O
peripheral	B:C0229664
blood	I:C0229664
,	O
tonsils	O
,	O
or	O
tumors	O
,	O
expressed	O
surface	I:C1608815
CD169	I:C1608815
.	O

T	I:C0242629
cells	I:C0242629
in	O
regional	O
LNs	I:C1179441
,	O
but	O
not	O
peripheral	O
blood	I:C0229664
,	O
tonsils	B:C0836921
,	O
or	O
tumors	O
,	O
expressed	O
surface	I:C1608815
CD169	I:C1608815
.	O

T	I:C0242629
cells	I:C0242629
in	O
regional	O
LNs	I:C1179441
,	O
but	O
not	O
peripheral	O
blood	I:C0229664
,	O
tonsils	O
,	O
or	O
tumors	B:C0027651
,	O
expressed	O
surface	I:C1608815
CD169	I:C1608815
.	O

T	I:C0242629
cells	I:C0242629
in	O
regional	O
LNs	I:C1179441
,	O
but	O
not	O
peripheral	O
blood	I:C0229664
,	O
tonsils	O
,	O
or	O
tumors	O
,	O
expressed	B:C1608815
surface	I:C1608815
CD169	I:C1608815
.	O

In	B:C0444498
situ	I:C0444498
detection	O
of	O
draining	O
LNs	I:C0024204
revealed	O
preferential	O
localization	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
situ	I:C0444498
detection	B:C1511790
of	O
draining	O
LNs	I:C0024204
revealed	O
preferential	O
localization	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
situ	I:C0444498
detection	O
of	O
draining	B:C0024204
LNs	I:C0024204
revealed	O
preferential	O
localization	O
of	O
CD169	O
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

In	O
situ	I:C0444498
detection	O
of	O
draining	O
LNs	I:C0024204
revealed	O
preferential	O
localization	O
of	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
to	O
subcapsular	B:C1518052
sinus	I:C1518052
and	O
interfollicular	O
regions	I:C1512836
,	O
closely	O
associated	O
with	O
CD169	O
(+)	I:C0024432

T	I:C0039194
cells	I:C0039194
to	O
subcapsular	O
sinus	I:C1518052
and	O
interfollicular	B:C1512836
regions	I:C1512836
,	O
closely	O
associated	O
with	O
CD169	O
(+)	I:C0024432

T	I:C0039194
cells	I:C0039194
to	O
subcapsular	O
sinus	I:C1518052
and	O
interfollicular	O
regions	I:C1512836
,	O
closely	O
associated	O
with	O
CD169	B:C0024432
(+)	I:C0024432

MÏ•.	I:C0024432
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cell	I:C0039194
ratios	O
were	O
significantly	O
lower	O
in	O
peri-tumor	O
lymph	B:C0024204
nodes	I:C0024204
than	O
distant	O
-	O
tumor	O
lymph	O
nodes	I:C0024204
.	O

T	I:C0039194
cell	I:C0039194
ratios	O
were	O
significantly	O
lower	O
in	O
peri-tumor	O
lymph	O
nodes	I:C0024204
than	O
distant	O
-	O
tumor	O
lymph	B:C0024204
nodes	I:C0024204
.	O

CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	B:C0005516
markers	I:C0005516
(	O
CD69	O
,	O
HLA	O
-	I:C0019764
DR	I:C0019764
,	O
PD	O
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	O
markers	I:C0005516
(	O
CD69	B:C0108800
,	O
HLA	O
-	I:C0019764
DR	I:C0019764
,	O
PD	O
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	O
markers	I:C0005516
(	O
CD69	O
,	O
HLA	B:C0019764
-	I:C0019764
DR	I:C0019764
,	O
PD	O
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	O
markers	I:C0005516
(	O
CD69	O
,	O
HLA	O
-	I:C0019764
DR	I:C0019764
,	O
PD	B:C0135710
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	O
markers	I:C0005516
(	O
CD69	O
,	O
HLA	O
-	I:C0019764
DR	I:C0019764
,	O
PD	O
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	B:C0108789
and	O
CD62L	O
levels	O
.	O

T	I:C0039194
cells	I:C0039194
predominantly	O
expressed	O
activation	O
markers	I:C0005516
(	O
CD69	O
,	O
HLA	O
-	I:C0019764
DR	I:C0019764
,	O
PD	O
-	I:C0135710
1	I:C0135710
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	B:C0125090
levels	O
.	O

They	O
produced	O
high	O
granzyme	B:C0061878
B	I:C0061878
,	O
perforin	O
,	O
TNF-Î±	O
,	O
and	O
IFN	O
Î³	I:C3539881
levels	O
,	O
and	O
promoted	O
tumor	O
-	I:C1446301
killing	I:C1446301
efficiency	I:C1446301
ex	O
vitro	O
.	O

They	O
produced	O
high	O
granzyme	O
B	I:C0061878
,	O
perforin	B:C0070410
,	O
TNF-Î±	O
,	O
and	O
IFN	O
Î³	I:C3539881
levels	O
,	O
and	O
promoted	O
tumor	O
-	I:C1446301
killing	I:C1446301
efficiency	I:C1446301
ex	O
vitro	O
.	O

They	O
produced	O
high	O
granzyme	O
B	I:C0061878
,	O
perforin	O
,	O
TNF-Î±	B:C1456820
,	O
and	O
IFN	O
Î³	I:C3539881
levels	O
,	O
and	O
promoted	O
tumor	O
-	I:C1446301
killing	I:C1446301
efficiency	I:C1446301
ex	O
vitro	O
.	O

They	O
produced	O
high	O
granzyme	O
B	I:C0061878
,	O
perforin	O
,	O
TNF-Î±	O
,	O
and	O
IFN	B:C3539881
Î³	I:C3539881
levels	O
,	O
and	O
promoted	O
tumor	O
-	I:C1446301
killing	I:C1446301
efficiency	I:C1446301
ex	O
vitro	O
.	O

They	O
produced	O
high	O
granzyme	O
B	I:C0061878
,	O
perforin	O
,	O
TNF-Î±	O
,	O
and	O
IFN	O
Î³	I:C3539881
levels	O
,	O
and	O
promoted	O
tumor	B:C1446301
-	I:C1446301
killing	I:C1446301
efficiency	I:C1446301
ex	O
vitro	O
.	O

Moreover	O
,	O
CD169	B:C0039194
(+)	I:C0039194
CD8	I:C0039194
(+)	I:C0039194

T	I:C0039194
cells	I:C0039194
infiltrating	B:C0332448
tumor	O
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
decreased	O
with	O
disease	O
progression	I:C0242656
and	O
were	O
strongly	O
associated	O
with	O
colorectal	O
cancer	I:C1527249
patient	O
survival	O
.	O

T	I:C0039194
cells	I:C0039194
infiltrating	O
tumor	B:C0024204
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
decreased	O
with	O
disease	O
progression	I:C0242656
and	O
were	O
strongly	O
associated	O
with	O
colorectal	O
cancer	I:C1527249
patient	O
survival	O
.	O

T	I:C0039194
cells	I:C0039194
infiltrating	O
tumor	O
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
decreased	O
with	O
disease	B:C0242656
progression	I:C0242656
and	O
were	O
strongly	O
associated	O
with	O
colorectal	O
cancer	I:C1527249
patient	O
survival	O
.	O

T	I:C0039194
cells	I:C0039194
infiltrating	O
tumor	O
-	I:C0024204
draining	I:C0024204
LNs	I:C0024204
decreased	O
with	O
disease	O
progression	I:C0242656
and	O
were	O
strongly	O
associated	O
with	O
colorectal	B:C1527249
cancer	I:C1527249
patient	O
survival	O
.	O

We	O
identified	O
novel	O
activated	O
/	O
cytolytic	B:C0039195
CD169	I:C0039195
(+)	I:C0039195
CD8	I:C0039195
(+)	I:C0039195

T	I:C0039195
cells	I:C0039195
selectively	O
present	O
in	O
regional	B:C1179441
LNs	I:C1179441
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	O
factor	I:C1514474
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	O
.	O

T	I:C0039195
cells	I:C0039195
selectively	O
present	O
in	O
regional	O
LNs	I:C1179441
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	B:C1514474
factor	I:C1514474
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	O
.	O

T	I:C0039195
cells	I:C0039195
selectively	O
present	O
in	O
regional	O
LNs	I:C1179441
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	O
factor	I:C1514474
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	B:C0021083
.	O

